Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670799 · ClinicalTrials.gov registry record · Early Phase 1
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01670799 is a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 29 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01670799, a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the anti-cancer effect of a pain medication called ketorolac (Toradol) on ovarian cancer cells in the abdominal (peritoneal) cavity after surgery for ovarian, fallopian tube or primary peritoneal cancer.
Conditions Studied
Interventions
- DRUG Ketorolac
Study Locations (1)
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670799
The ClinicalTrials.gov registry entry for NCT01670799 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac is the first listed.
NCT01670799 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT01670799 about?
NCT01670799 is a clinical study titled "Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer". The purpose of this study is to evaluate the anti-cancer effect of a pain medication called ketorolac (Toradol) on ovarian cancer cells in the abdominal (peritoneal) cavity after surgery for ovarian, fallopian tube or primary peritoneal cancer.
What is the current status of trial NCT01670799?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2012-03. Estimated completion is 2015-12.
What conditions does trial NCT01670799 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT01670799?
The interventions under investigation include: Ketorolac (DRUG).
Who is sponsoring clinical trial NCT01670799?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01670799 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.